Table 1.
Baseline demographic and clinical characteristics of the patients.
| Patient # | Sex/Gender | Age (years) | Distance from MS centre (km) | Disease phenotype | Years on MS diagnosis | Comorbidities | EDSS before relapse | DMT | Time on last DMT (years) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 49 | 59 | NMOSD | 0.2 | Hypothyroidism | 5 | No treatment | NA |
| 2 | F | 35 | 43 | RR MS | 13 | Chronic anaemia | 2 | Dimethyl fumarate | 3 |
| 3 | M | 50 | 149 | RR MS | 20 | No | 3 | Teriflunomide | 1 |
| 4 | M | 46 | 149 | RR MS | 15 | Hypertension/Obesity | 3.5 | Teriflunomide | 1 |
| 5 | M | 50 | 61 | RR MS | 20 | No | 3.5 | Teriflunomide | 3 |
| 6 | F | 36 | 77 | RR MS | 9 | Achondroplasia | 2.5 | Dimethyl fumarate | 5 |
| 7 | F | 31 | 435 | RR MS | 2 | No | 2 | Teriflunomide | 1 |
| 8 | F | 25 | 12 | RR MS | 5 | No | 2/2.5 | Teriflunomide | 3 |
| 9 | F | 39 | 110 | RR MS | 1 | Hypothyroidism | 2 | No treatment | NA |
| 10 | F | 39 | 149 | RR MS | 7 | No | 1.5 | Teriflunomide | 1.5 |
| 11 | F | 40 | 5 | RR MS | 7 | No | 2.5 | Dimethyl fumarate | 1 month |
DMT: disease modifying therapy; EDSS: Expanded Disability Status Scale; MS: multiple sclerosis; NA: not applicable; NMOSD: neuromyelitis optica spectrum disease; RR: relapsing remitting.